Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

June 23, 2026

IMUNON to Present at the Life Sciences Investor Forum on June 25th

June 22, 2026

IMUNON Announces Up to $10 Million Cash Financing

June 4, 2026

Financial Events

Imunon First Quarter 2026 Financial Results

May 12, 2026 at 11:00 AM EDT

Presentation at the MedInvest Biotech and Pharma Investor Conference

April 1, 2026